Our News

Press Releases
Presentations

April 20, 2026 | American Association for Cancer Research (AACR) Immune Escape via Myeloid-Derived Suppressor Cells in Solid Tumor Cancer Patients Treated with Anchored IL-12 (Tolododekin Alfa)
Anchored IL-12 (Tolododekin Alfa)

April 20, 2026 | American Association for Cancer Research (AACR) Intratumoral IL-12 in combination with HDAC inhibition overcomes checkpoint-refractory tumors Anchored IL-12 (Tolododekin Alfa)

Nov 9, 2025 | Society of Immunotherapy of Cancer (SITC) Baseline NKT cells as a potential predictive biomarker for treatment with an anchored IL-12 drug conjugate in patients with solid tumors

Nov 9, 2025 | Society of Immunotherapy of Cancer (SITC) Alum-anchored CD40 antibody drug conjugate (ANK-201) promotes local anti-tumor immunity and therapeutic activity without systemic toxicity in preclinical tumor modelsesults of a first-in-human Phase 1 trial of anchored IL-12 drug conjugate (ANK-101)

Nov 9, 2025 | Society of Immunotherapy of Cancer (SITC)Evaluation of Alum-Anchored IL-12 (JEN-101) Immunotherapy of Canine Melanoma

Apr 28, 2025 | American Association for Cancer Research (AACR)Results of a first-in-human Phase 1 trial of anchored IL-12 drug conjugate (ANK-101)

Nov 9, 2024 | Society of Immunotherapy of Cancer (SITC):A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors

Nov 8, 2024 | Society of Immunotherapy of Cancer (SITC):Anchored immunotherapy with alum-tethered canine interleukin-12 (JEN-101) is safe and induces therapeutic responses: Results of a preclinical investigation in dogs with advanced melanoma

Jun 1, 2024 | American Society of Clinical Oncology (ASCO):A Phase 1, Open-Label, Dose Escalation Study of the Safety and Tolerability of ANK-101 in Advanced Solid Tumors

Apr 5, 2024 | American Association for Cancer Research (AACR):Anchored IL-12 synergizes with an epigenetic modulator to promote immune remodeling and overcome anti-PD1-refractory murine tumors

Nov 3, 2023 | Society for Immunotherapy of Cancer (SITC):Improved immunologic and therapeutic activity of anchored interleukin (IL)-12 immunotherapy in combination with cytotoxic chemotherapy and immune checkpoint inhibitor in a head and neck cancer model

Oct 14, 2023 | Veterinary Cancer Society:Tolerability and Activity of Anchored Canine Interleukin-12 (cANK-101) in Pet Dogs with Advanced Malignant Melanoma

Oct 12, 2023 | European Organization for Research and Treatment of Cancer (EORTC):Preclinical pharmacokinetic (PK) and tumour growth inhibition (TGI) modelling for mANK-101, an anchored murine interleukin-12 (IL-12) complex for intratumoural administration for solid cancer

Apr 19, 2023 | American Association for Cancer Research (AACR)Preliminary Results of an Exploratory Phase I Clinical Trial of Anchored Canine Interleukin-12 (cANK-101) in Dogs with Advanced Oral Malignant Melanoma

Nov 10, 2022 | Society for Immunotherapy of Cancer (SITC) Presentation:Anchored immunotherapy with intratumorally administered aluminum hydroxide-tethered IL-12 induces potent anti-tumor immune response

Apr 10, 2022 | American Association for Cancer Research (AACR) Presentation:Intratumoral delivery of aluminum hydroxide-tethered IL-12 induces potent anti-tumor immune response

Oct 14, 2021 | Society for Immunotherapy of Cancer (SITC) Presentation:Intratumoral immunotherapy with aluminum hydroxide-tethered IL-12 induces potent local and systemic immunity with minimal toxicity

Publications

Sep 29, 2025 | Nature Communications: Interleukin-12 anchored drug conjugate (tolododekin alfa) in patients with advanced solid tumors: first-in-human Phase 1 trial

Mar 13, 2025 | Molecular Cancer Therapeutics: A Pharmacokinetic and Pharmacodynamic Model of an IL-12 Anchored-Drug Conjugate for the Treatment of Solid Tumors

Oct 7, 2024 | Journal for ImmunoTherapy of Cancer:Alum-anchored IL-12 combined with cytotoxic chemotherapy and immune checkpoint blockade enhanced antitumor immune responses in head and neck cancer models

Dec 8, 2023 | JCI Insight:Intratumoral aluminum hydroxide–anchored IL-12 drives potent antitumor activity by remodeling the tumor microenvironment

Jan 10, 2022 | Nature Biomedical Engineering:Intratumourally injected alum-tethered cytokines elicit potent and safer local and systemic anticancer immunity

Jun 2, 2022 | Expert Opinion on Drug Delivery Manuscript:Intratumorally anchored cytokine therapy

Media

May 15, 2025 | PBS.org: The Cancer Pioneers